Dominant-negative transforming growth factor beta receptor II (DN-TGFβRII)

The **dominant-negative transforming growth factor beta receptor II** (*DN-TGFβRII*) is a genetically engineered mutant of the native type II transforming growth factor beta receptor. The wild-type **transforming growth factor beta receptor II** (*TGFBR2*) is a serine/threonine kinase transmembrane protein that binds transforming growth factor beta (TGF-beta) ligands and forms a heterodimeric complex with type I receptors, initiating intracellular signal transduction pathways that regulate cell proliferation, differentiation, apoptosis, and extracellular matrix production[1][2]. Mutations in *TGFBR2* are associated with several connective tissue disorders and various cancers due to its role as a tumor suppressor[1][2]. The "dominant-negative" version refers specifically to an engineered mutant that lacks functional kinase activity but retains ligand binding. When expressed in cells, this mutant competes with endogenous receptors for ligand binding but cannot propagate downstream signals. As such, it acts as an inhibitor of normal TGF-beta signaling pathways. This approach is widely used in research models—especially cancer biology—to study loss-of-function effects of TGF-beta signaling or as an experimental therapeutic strategy[3]. There are no approved drugs targeting DN-TGFβRII itself; rather, it serves as a tool molecule for blocking endogenous pathway activity. Its use outside laboratory settings remains investigational due to potential safety concerns related to broad inhibition of physiological processes regulated by TGF-beta signaling[3]. Note: The term "DN-TGFβRII" does not refer to an endogenous human protein but rather describes an artificial construct used primarily in research contexts. For structured data purposes about natural targets relevant for drug discovery or clinical application, information should be mapped instead onto "Transforming growth factor beta receptor II" (*TGFBR2*), unless specifically discussing gene therapy vectors or model systems expressing this dominant-negative variant[1][2].

Other names

Dominant-negative TGF-beta receptor IIDN-TGFBR2TGFBR2 (when referring to the wild-type, not dominant-negative form)

The dominant-negative variant is used experimentally to block endogenous TGF-beta signaling by preventing normal receptor function.